复方甘草酸苷注射液治疗过敏性紫癜临床疗效及安全性观察  

Clinical effect and safety observation of compound glycyrrhizin injection in the treatment of Anaphylactoid purpura

作　　者：刘磊[1] 张晓彬[1] 

机构地区：[1]河南信阳职业技术学院附属医院,河南信阳464000

出　　处：《中国医药科学》2014年第11期83-85,共3页China Medicine And Pharmacy

摘　　要：目的观察复方甘草酸苷治疗过敏性紫癜的临床疗效和安全性。方法采用对比法将60例过敏性紫癜患者随机分为两组：对照组常规治疗，抗组胺药、维生素C、芦丁及对症治疗，关节型、胃肠道型、肾型、混合型患者加用甲泼尼龙针1～2mg／（kg·d）静脉滴注，好转后减量；治疗组在以上对照组常规治疗基础上加用复方甘草酸苷（美能）注射液，≤12岁10mL／d，〉12岁20mL／d，静脉滴注，疗程均12d，观察患者症状及皮损恢复情况。结果治疗组有效率为93．3％，对照组有效率为73．3％，两组比较，有显著性差异（x^2=4．320，P〈0．05）。治疗组的痊愈率及有效率均明显高于对照组。不良反应可以耐受且停药后自行消失。结论复方甘草酸苷治疗过敏性紫癜安全有效，有较高临床应用价值，值得临床推广。Objective To observe the clinical efficacy and security of compound glycyrrhizin injection in the treatment of Anaphylactoid purpura. Methods 60 patients with Anapbylactoid purpura were randomly divided into two groups using contrast method,Control group was given routine treatment, antihistamines, vitamin C, rutin and symptomatic treatment,the kinds of joint, gastrointestinal tract,kidney type,mixed were added in a needle of prednisolone 1-2mg/（kg ~ d） by intravenous drip, and the dosage was reducted after symptoms improved;while the treatment group was given the compound glycyrrhizin injection（meineng）,intravenous infusion of 10mL/d for 〈 12- year-old and 20 mL/d for 〉 12 years old. in addition to the treatment in the control group,The clinical efficacy of conjunction use of 12 days was observed.The symptoms and skin recovery were observed. Results The total effective rate of treatment group was 93.3%,which was significantly better than that in the control group （73.3%）, the difference was statistically significant（x^2 =4.320,P 〈 0.05）.The cure rate and effective rate in treatment group were significantly higher than that in the control group. Adverse reactions can be tolerated and go away after drug withdrawal. Conclusion compound glycyrrhizin injection was safe and effective in the treatment of Anaphylactoid purpura,had higher clinical value,and was worthy of clinical promotion.

关 键 词：复方甘草酸苷 过敏性紫癜 临床疗效 安全性 

分 类 号：R554.6[医药卫生—血液循环系统疾病]